FLOT chemotherapy significantly improves survival in patients with cT2cN0 adenocarcinoma of the esophagus compared to chemoradiotherapy.

• Mean survival: 100.8 months for FLOT vs. 74.6 months for CROSS (p = 0.028).
• Three-year survival rates: 87% for FLOT vs. 59% for CROSS.

Surgeons should prioritize FLOT treatment in multimodal approaches for these patients to enhance outcomes.

• 23.3% of FLOT patients underwent gastrectomy versus 6.8% in the CROSS group (p = 0.007).